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be performed using either transperitoneal or retroperitoneal techniques.
The advantages of retroperitoneal approach were avoidance of bowel
manipulation and it could be direct access to the kidney. Thus the aim of
our study was to evaluate the experience of laparoscopic retroperitoneo-
scopic partial nephrectomy for angiomyolipoma in our center.
Materials and Methods: We retrospectively analyzed the medical records
of 20 patients (17 females and 3 males) who underwent retroperitoneal
laparoscopic partial nephrectomies for benign renal tumor (pathology:
angiomyolipoma) in Chi-Mei Medical Center from June 2012 to July 2015.
All of the surgeries were performed by a single surgeon. The demographic
data, characteristic of tumors, peri-operative status and post-operative
outcome were analyzed.
Results: Twenty-two partial nephrectomies were performed in twenty-one
kidneys. The mean age was 48-year-old (27-70). Most of the patients were
diagnosed incidentally, only 4patients (20%) presentedwith the symptomof
ﬂank or abdominal pain. Themean size of tumorswhich disclosed by CTwas
4.9 cm (1-18). Meanwhile the R.E.N.A.L nephrometry score was 6.1 in
average. Only one patient who underwent pre-operative TAE due to huge
tumor size (18cm). There was a wide range of operative time with mean
176 mins (90-345) related to the complexity of tumors. The average warm
ischemic time was 9.4 mins (0-20.7) with 7 partial nephrectomies done in
zero-ischemia status. Intra-operative estimated blood loss 173 ml (10-600).
No major surgical complications noted. Only 3 patients required blood
transfusionperioperatively. Another one patient experienced asymptomatic
perirenal hematomaduringCT follow-up. Theaveragepost-operative length
of hospital stay was 3.3 days (2-8). Regarding the renal function, the average
decreased of GFRof lesion side after operationwas 11% (from 46.5ml/min to
41.4 ml/min). Two patients revealed residual tumors and one patients
showed tumor recurrence by CT during out-patient department follow-up.
Conclusion: Laparoscopic retroperitoneoscopic renal surgery can be per-
formed safely and effectively. However, the limited space of retro-
peritoneum given this procedure more challenging.
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THULIUM LASER FOR TRANSURETHRAL RESECTION OF BLADDER
TUMORS
Guang-Dar Juang 1,2, Thomas I-sheng Hwang 1,2,3, Te-Fu Tsai 1,2. 1Division
of Urology, Department of Surgery, Shin-Kong WHS Memorial Hospital,
Taipei, Taiwan; 2 School of Medicine, Fu-Jen Catholic University, New Taipei
City, Taiwan; 3 School of Medicine, Taipei Medical University, Taipei, Taiwan
Purpose: We describe the preliminary experience of a new method by
Thulium laser for transurethral resection of CIS or diffuse sessile bladder
tumors.
Materials and Methods: From September 2014 to December 2015, 7 pa-
tients (6 males and 1 female) newly diagnosed with having diffuse sessile
bladder tumors with or without ureteral oriﬁce involved were selected by
TUR-BT of Thulium Laser. A 10-20 watts Thulium laser power was used to
incise bladder tumors by 300-microm ﬁber through resectoscope. Mean
tumor diameter was 5.5cm (range 3.5e9.0)
Results: All patients were treated successfully in one secession. No pa-
tients experienced detrusor nerve reﬂection intra-operatively and no
bladder perforation in dome-located neoplasm. Mean operative time was
55 min (range 30e100). Tumors involved ureteral meatus were noted in 3
patients. The oriﬁce was sharply excised without subsequent evidence of
stenosis. The mean follow-up time was 8.4 months. Tumor recurrences
were found in two patients in 6 and 12 months postoperatively.
Conclusion: In our limited experience, Thulium laser TURBT is a reliable
therapy with minimal morbidity for selected patients of diffuse bladder
tumors with ureteral oriﬁce involved or CIS.
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UP-REGULATION OF PROSTATIC CANNABINOID RECEPTOR TYPE 2
FOLLOWING CAPSAICIN-INDUCED PROSTATITIS IN CASTRATED AND
NON-CASTRATED RATS
Alex Tong-Long Lin 1,2, Wei-Ming Cheng 3, Yu-Ju Shih 1,2, C.L. Yang 1,2,
Kuang-Kuo Chen 1,2. 1Department of Urology, Taipei Veterans GeneralHospital, Taipei, Taiwan; 2Department of Urology, School of Medicine,
National Yang-Ming University, Taiwan; 3 Zhongxiao Branch, Taipei City
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Purpose: The etiology of chronic prostatitis/chronic pelvic pain syndrome
(CP/CPPS) is unknown, and there are still no established treatments that
consistently relieve patients' symptoms. Endocannabinoids serves as
important modulators of tissue inﬂammation and pain perception.
Manipulation of cannabinoid system had been shown to reduce inﬂam-
mation and lessen pain perception in some inﬂammatory disorders. This
study investigated the changes of cannabinoid system following capsaicin-
induced prostatitis in castrated and non-castrated rats.
Materials and Methods: In adult male Sprague-Dawley rats androgen
deprivation was induced with bilateral orchiectomy (OX). At 4 weeks after
bilateral OX or sham operation, prostate inﬂammation was induced by
intraprostatic capsaicin injection. Control group received intraprostatic
vehicle injection. The expression of cannabinoid receptor type 1(CB1) and
2(CB2), fatty amide hydrolase (FAAH) and cyclooxygenase 2(COX-2) in
each group were examined with RT-PCR for mRNA and
immunohistochemistry.
Results: Capsaicin injection induced an inﬂammatory reaction with inﬁl-
tration of leukocytes. Expression of COX-2 was enhanced following
capsaicin injection. Capsaicin injection increased CB2 expression, while
the expression of CB1 was not changed. Expression of FAAH, a endo-
cannabinoid degradation enzyme, was reduced following capsaicin in-
jection. Castration induced an atrophic change of the prostate gland.
Expression of CB1, CB2 and FAAH was enhanced following castration.
Capsaicin injection also induced an inﬂammatory reaction in the cas-
trated-prostate, but with a lesser degree of leukocyte accumulation as
compared with non-castrated group. In the castrated-prostate capsaicin
injection induced a further increase of CB2 expression, while expression of
CB1 and FAAH was not changed.
Conclusion: The present study demonstrated a consistent up-regulation
of CB2 following capsaicin-induced prostatitis in castrated and non-cas-
trated rats. CB2 can be a promising therapeutic target in treating non-
bacterial prostatitis.
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Yu Khun Lee, Hann-Chorng Kuo. Department of Urology, Hualien Tzu Chi
Hospital, Huelien, Taiwan
Purpose: To assess the therapeutic efﬁcacy and safety of mirabegron
25 mg once daily in very old and frail patients with overactive bladder
(OAB) and multiple comorbidities compared with younger patients.
Materials and Methods: Patients with OAB at the age range of between
twenty to sixty years old and over eighty years old were included in this
study. All of the participants were treatment-naive or no treatment more 3
months at the baseline, treated with mirabegron 25 mg once daily. The
patients were divided into two groups, younger (20-60 years old) and
older(S 80 years old). Patients who discontinued mirabegron 25 mg once
daily; or changed the dosage of mirabegron; or changed to antimuscarinics
during treatment course were excluded. Their underlying comorbidities
was recorded. Assessment tools included International Prostate Symptom
Score (IPSS), Overactive Bladder Symptom Score (OABSS), Urgency Severity
Score (USS), Patient Perception of Bladder Condition (PPBC), Quality of Life
(QoL), uroﬂowmetry and prostate volume. We compared the difference of
the change from baseline to 1st month and 3rd month between two groups.
Safety assessments included reporting adverse events (AEs) and post-void
residual.
Results: Total 92 patients (younger, N¼56; very older, N¼40) with OAB
treated with mirabegron 25 mg once daily were included. The mean age of
younger group was 50.55 ± 10.12 and older group was 85.58 ± 3.76. In
overall, the patients in the older group have more underlying comorbid-
ities than younger group (59 vs 30). There was no signiﬁcant difference of
baseline in IPSS, OABSS, USS, QoL and total prostate volume (TPV) between
two groups. However, the baseline Qmax, voided volume, post-voided
residual (PVR) and PPBC were lower in older group. A statistically
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baseline in younger group (P<0.05). In older group, the score of QoL and
OABSS were signiﬁcantly decreased at 1st and 3rd month compared with
baseline. (P<0.05).The mean changes of most measurements after 3
months of treatment were no signiﬁcant difference between younger and
older patients, except Qmax and voided volume. Younger patients expe-
rience more AEs than the elders (26.79% vs 12.5%) during treatment. The
common AEs included dry mouth (n¼5), abdominal distension (n¼3) and
dizziness (n¼3). Nevertheless, the incidence of AEs when using mirabe-
gron were acceptable low in two groups.
Conclusion: Mirabegron 25 mg once daily is a safe and effective drug to
improve OAB symptoms and QoL in old patients with multiple comor-
bidities. The treatment efﬁcacy were no much difference between younger
and older patients.
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SUBJECTIVE SYMPTOM IMPROVEMENT OF SILODOSIN TREATMENT FOR
BPH PATIENTS WITH UNSATISFACTORY RESPONSE TO INITIAL ɑ1
BLOCKER
Han-Yu Weng, Chien-Hui Ou. Department of Urology, Medical College and
Hospital, National Cheng-Kung University, Tainan, Taiwan
Purpose: To evaluate subjective symptoms improvement of Silodosin
treatment for BPH patients with unsatisfactory response to initial ɑ1
blocker.
Materials and Methods: 50 patients diagnosed with BPH and reported
with unsatisfactory response to initial ɑ1 blocker were included in this
study. IPSS were recorded before and after administration of 4 weeks of
Silodosin. No drug withdrawal period was provided when switching the
drug. We evaluate subjective improvement of Silodosin treatment ac-
cording to the International Prostate Symptom Score.
Results: 28 patients (56 %) had subjective improvement according to the
International Prostate Symptom Score total score but 22 patients failed to
have symptoms improvement. Comparison of symptoms revealed that
Silodosin showed signiﬁcant effect on nocturia. The most frequent adverse
drug reaction was ejaculatory disorder with Silodosin.
Conclusion: Silodosin exhibits some efﬁcacy in improving subjective
symptoms especially in nocturia for BPH patients with unsatisfactory
response to initial ɑ1 blocker
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WHETHER A GOOD UROFLOW RATE COULD GUARANTEE A LOW POST-
VOID RESIDUAL URINE VOLUME IN MEN WITH OVERACTIVE BLADDER?
Kuan-Jung Lin 1, Chih-Chieh Lin 1,2,3, Alex Tong-Long Lin 1,2,3, Kuang-Kuo
Chen 1,2,3. 1Department of Urology, Taipei Veterans General Hospital, Taipei,
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Purpose: When considering antimuscarinics for patients with overactive
bladder (OAB), post-void residual urine volume (PVR) is an important
factor for decision-making. Using antimuscarinics in patients with a large
amount PVR is not desirable. It is a reasonable inference that patients with
good ﬂow rates should be able to empty their bladders to achieve a low
PVR. If this hypothesis is correct, then antimuscarinics can be used safely in
OAB patients with good ﬂow rate without the need to check PVR. This
study tested this hypothesis by evaluating the correlation between uroﬂow
rate and PVR in men with OAB symptom.
Materials and Methods: We retrospectively recruited male OAB patients,
who had urgency with or without urge incontinence, between Aug 2008
and July 2015. Exclusion criteria included urinary tract infection, prostate
and bladder cancer. Patients with abdominal strain pattern or inadequate
voided volume (less than 150ml) on uroﬂowmetry (UFR) were excluded.
Patients were categorized into good Qmax and low Qmax groups by the
cut-off value of 15ml/sec maximal ﬂow rate (Qmax) in free uroﬂowmetry.
All patients received pressure ﬂow studies for evaluating bladder outlet
obstruction (BOO) and transabdominal ultrasonography for evaluating the
prostatic size, intra-vesical prostatic protrusion (IPP) and detrusor wall
thickness (DWT). BOO was deﬁned by BOOI>40. Amounts of residual urinewere determined by post-void catheterization. International Prostate
Symptom Score (IPSS) and Overactive Bladder Symptom Score (OABSS)
were collected for symptom evaluation.
Results: A total of 136 male patients with OAB symptoms were enrolled.
The patients’ demographic was showed in table 1. Patients with good
Qmax group were signiﬁcantly younger. Patients with good Qmax had
lower scores in the total score of IPSS and voiding subscore. Nocturia as
evaluated by IPSS and OABSS was more severe in patients with low Qmax
group. PVR in good Qmax group was signiﬁcantly less than that in low
Qmax group (49.3±39.0 vs 82.7±79.6, p¼0.04). However, in good Qmax
group, 15.7% patients had PVR more than 100ml and 7.1% had PVR more
than 200ml. More patients in low Qmax group had BOO than those in good
Qmax group (48.6% vs 24.2%, p¼0.03)
Conclusion: Male OAB patients with maximal uroﬂow rate higher than
15ml/sec have lower PVR. Nevertheless, clinical signiﬁcant high PVRmight
still present in patients with good ﬂow rate. It is still necessary to measure
PVR even in patients with a satisfactory uroﬂow rate.
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THE EFFECT OF LOW-INTENSITY EXTRACORPOREAL SHOCK WAVE
THERAPY FOR CHRONIC PELVIC PAIN SYNDROME
Chia-Chun Tsai 1,2, Chia-Chu Liu 1,2,3, Hsiang-Ying Lee 1,2, Jiun-Hung
Geng 1,4, Ching-Chia Li 1,2, Wen-Jeng Wu1,2, Chii-Jye Wang 1. 1Department
of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan;
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Purpose: To assess the safety and efﬁcacy of the treatments performed
with low-intensity extracorporeal shockwave therapy (LI-ESWT) on
symptomatic chronic pelvic pain syndrome (CPPS) patients.
Materials and Methods: We design a prospective, blind and randomized
controlled trial for patients with CPPS. All patients have once LI-ESWT per
week for 4 weeks. Use questionnaire of pre-treatment and post-treatment
to assess the safety and efﬁcacy.
Results: The National Institutes of Health Chronic Prostatitis Symptom
Index (NIH-CPSI) scores, especially CPSI pain domain, of enrolled patient
were improved after 4 times LI-ESWT. More than half patients who got LI-
ESWT had symptomatic improvement after ﬁst treatment. There is a ten-
dency to improve sexual quality after full therapeutic regimen. No patients
have ecchymosis, intolerable pain or other complication during LI-ESWT.
Conclusion: We describe our experience of LI-ESWT for CPPS patients. In
this pilot study, LI-ESWT can improve quality of life for CPPS patients
without complications.
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SALVAGE RADIOTHERAPY FOR RECURRENCE OF LOCALIZED PROSTATE
CANCER AFTER HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU)
Yen-Ting Wu 1,2, Guan-Lin Huang 1,2, Fu-Min Fang 1,2, You-Ming Wang 1,2,
Chun-Chien Hsu 1,2, Yao-Chi Chuang 1,2, Po-Hui Chiang 1,2. 1Department of
Urology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan;
2Department of Radiation Oncology, Kaohsiung Chang Gung Memorial
Hospital, Kaohsiung, Taiwan
Purpose: Despite increasing application of high-intensity focused ultra-
sound (HIFU), there was few published experience regarding to salvage
management for recurrent localized prostate cancer. We aim to evaluate
tolerance and oncologic control with salvage radiotherapy (SRT) after HIFU
failure and to identify predictive factors of success.
Materials and Methods: In this single-centre retrospective study, retro-
spective analysis on 121 localized prostate cancer patients status post the
HIFU therapy from December 2009 to July 2015 were performed with
perioperative data. Total 11 patients underwent salvage radiotherapy with
dose ranging from 2400-7200 cGy. The median dose of conformal treat-
ment was 7000 cGy. The primary outcome measure was progression-free
